1. Home
  2. COLL vs CPF Comparison

COLL vs CPF Comparison

Compare COLL & CPF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COLL
  • CPF
  • Stock Information
  • Founded
  • COLL 2002
  • CPF 1954
  • Country
  • COLL United States
  • CPF United States
  • Employees
  • COLL N/A
  • CPF N/A
  • Industry
  • COLL Biotechnology: Pharmaceutical Preparations
  • CPF Major Banks
  • Sector
  • COLL Health Care
  • CPF Finance
  • Exchange
  • COLL Nasdaq
  • CPF Nasdaq
  • Market Cap
  • COLL 958.8M
  • CPF 849.9M
  • IPO Year
  • COLL 2015
  • CPF N/A
  • Fundamental
  • Price
  • COLL $36.04
  • CPF $31.20
  • Analyst Decision
  • COLL Strong Buy
  • CPF Buy
  • Analyst Count
  • COLL 4
  • CPF 1
  • Target Price
  • COLL $44.25
  • CPF $35.00
  • AVG Volume (30 Days)
  • COLL 463.5K
  • CPF 152.6K
  • Earning Date
  • COLL 11-06-2025
  • CPF 10-29-2025
  • Dividend Yield
  • COLL N/A
  • CPF 3.60%
  • EPS Growth
  • COLL N/A
  • CPF 6.71
  • EPS
  • COLL 1.06
  • CPF 2.24
  • Revenue
  • COLL $707,007,000.00
  • CPF $253,738,000.00
  • Revenue This Year
  • COLL $22.23
  • CPF $1.89
  • Revenue Next Year
  • COLL $2.78
  • CPF $6.03
  • P/E Ratio
  • COLL $34.38
  • CPF $13.39
  • Revenue Growth
  • COLL 22.61
  • CPF 6.60
  • 52 Week Low
  • COLL $23.23
  • CPF $23.16
  • 52 Week High
  • COLL $42.29
  • CPF $33.25
  • Technical
  • Relative Strength Index (RSI)
  • COLL 45.96
  • CPF 62.25
  • Support Level
  • COLL $34.71
  • CPF $29.75
  • Resistance Level
  • COLL $36.57
  • CPF $30.90
  • Average True Range (ATR)
  • COLL 1.25
  • CPF 0.61
  • MACD
  • COLL -0.59
  • CPF -0.14
  • Stochastic Oscillator
  • COLL 25.25
  • CPF 69.44

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

About CPF Central Pacific Financial Corp New

Central Pacific Financial Corp operates in the financial services sector in the United States. It is a full-service commercial bank offering a broad range of banking products and services, including accepting time and demand deposits and originating loans. Bank's deposits are insured by the Federal Deposit Insurance Corporation (FDIC) up to applicable limits. The bank is not a member of the Federal Reserve System. The company's loans include commercial loans, construction loans, commercial and residential mortgage loans, and consumer loans. The company derives income from interest and fees on loans, interest on investment securities, and fees received in connection with deposits and other services.

Share on Social Networks: